Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics
SRRK Stock Summary
- With a price/sales ratio of 91.84, Scholar Rock Holding Corp has a higher such ratio than 96.23% of stocks in our set.
- With a year-over-year growth in debt of 491.12%, Scholar Rock Holding Corp's debt growth rate surpasses 96.8% of about US stocks.
- In terms of volatility of its share price, SRRK is more volatile than 93.97% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Scholar Rock Holding Corp are CMRX, ALPN, GLYC, SGMO, and EDIT.
- SRRK's SEC filings can be seen here. And to visit Scholar Rock Holding Corp's official web site, go to scholarrock.com.
SRRK Stock Price Chart Interactive Chart >
SRRK Price/Volume Stats
| Current price | $51.33 | 52-week high | $66.72 |
| Prev. close | $53.35 | 52-week low | $9.53 |
| Day low | $50.00 | Volume | 151,083 |
| Day high | $54.00 | Avg. volume | 210,717 |
| 50-day MA | $53.51 | Dividend yield | N/A |
| 200-day MA | $30.33 | Market Cap | 1.73B |
Scholar Rock Holding Corporation (SRRK) Company Bio
Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Latest SRRK News From Around the Web
Below are the latest news stories about Scholar Rock Holding Corp that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock Announces Senior Management PromotionsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President, |
Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development SummitScholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit. |
Scholar Rock Provides Corporate Update and Highlights Priorities for 2021CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a corporate update and highlighted priorities for 2021. “2020 was a transformative year for Scholar Rock with significant progress made both clinically and operationally with positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s poten |
Earnings Update: Scholar Rock Holding Corporation (NASDAQ:SRRK) Just Reported And Analysts Are Boosting Their EstimatesScholar Rock Holding Corporation (NASDAQ:SRRK) just released its latest quarterly report and things are not looking... |
Scholar Rock to Present at Upcoming Healthcare ConferencesScholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming virtual investor conferences: |
SRRK Price Returns
| 1-mo | -12.90% |
| 3-mo | 18.44% |
| 6-mo | 255.22% |
| 1-year | 250.61% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 5.77% |
| 2020 | 268.21% |
| 2019 | -42.62% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching SRRK
Here are a few links from around the web to help you further your research on Scholar Rock Holding Corp's stock as an investment opportunity:Scholar Rock Holding Corp (SRRK) Stock Price | Nasdaq
Scholar Rock Holding Corp (SRRK) Stock Quote, History and News - Yahoo Finance
Scholar Rock Holding Corp (SRRK) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...